Tango Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Tango Therapeutics

27/03/2023 13:01

* Tango Therapeutics Inc  TNGX.OQ  reported a quarterly
adjusted
loss of 33 cents​​ per share for the quarter ended in December.
The mean expectation of six analysts for the quarter was for a
loss of 35 cents per share.
    * Revenue rose 12.2% to $6.41 million from a year ago;
analysts
expected $6.44 million. 
    * Tango Therapeutics Inc's reported EPS for the quarter was
a loss
of 33 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Tango Therapeutics Inc shares had fallen by 42.5% this
quarter.
    * The company reported a quarterly loss of $29.06 million.
    * Wall Street's median 12-month price target for Tango
Therapeutics Inc is $13.50 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 27 at 12:00 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.35          -0.33          Beat
 Sep. 30 2022      -0.32          -0.33          Missed
 Jun. 30 2022      -0.32          -0.28          Beat
 Mar. 31 2022      -0.28          -0.29          Missed